Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure

American Heart Journal

Volumn 138, Issue 4 I, 1999, Pages 654-662

  Brunner La Rocca, H P ^a   Weilenmann, D ^a   Kiowski, W ^a   Maly, F E ^a   Candinas, R ^a   Follath, F ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENALAPRILAT; NEUROHORMONE; NORADRENALIN; OXYGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SPIROMETRY;

EID: 0032888607     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70179-1     Document Type: Article

References (40)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
4. Cleland JG, Hubbard WN, Pittard J, Poole Wilson PA, Sutton GC. ACE inhibitors in heart failure. What dose? Postgrad Med J 1995;71:65-6.
5. Nussberger J, Fleck E, Bahrmann H, Delius W, Schultheiss HP, Brunner HR. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Dusseldorf, Munich, Germany. Eur Heart J 1994;15(Suppl D):113-22.
6. Pacher R, Stanek B, Globits S, et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heartfailure. Eur Heart J 1996;17:1223-32.
7. Davidson NC, Coutie W J, Webb DJ, Struthers AD. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 1996;75:576-81.
8. Riegger GA. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J 1991;12:705-11.
9. Corder CN, Rubler S, Deere LF, et al. Effect of cilazapril on exercise tolerance in congestive heart failure. Pharmacology 1993;46:148-54.
10. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19:481-9.
11. Valdemarsson S, Bergdahl A, Edvinsson L. Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure. J Intern Med 1994;235:595-601.
12. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds L, Wilson J. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
13. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Cardiol 1995;26:1257-63.
14. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and longterm survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
15. Bauch HJ, Kelsch U, Hauss WH. Einfache, schnelle, selektive und quantitative Bestimmung von Adrenalin und Noradrenalin im Plasma durch Kombination von Fliissigextraktion, HPLC-Trennung und elektrochemischer Detektion. J Clin Chem Clin Biochem 1986;24:651-8.
16. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996;27:345-52.
17. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
18. Stevenson LW, Steimle AE, Fonarow G, et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995;25:163-70.
19. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;94:2285-96.
20. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor I-IL. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation 1974;50:1179-89.
21. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system. Circulation 1991;83:1849-65.
22. Parodi O, DeMaria R, Oltrona L, et al. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation 1993;88:509-22.
23. Sabbah HN, Sharov VG, Cook JM, Shimoyama H, Lesch M. Accumulation of collagen in the cardiac interstitium of dogs with chronic heart failure is associated with decreased capillary density and increased oxygen diffusion distance [abstract]. J Am Coll Cardiol 1995;25:222A.
24. Schwartz K, Carrier L, Mercadier JJ, Lompre AM, Boheler KR. Molecular phenotype of the hypertrophied and failing myocardium. Circulation 1993;87(suppl VII):VII-5-VII-10.
25. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
26. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
27. Cleland JG, Semple P, Hodsman P, Ball S, Ford I, Dargie H. Angiotensin II levels, hemodynamics and sympathoadrenal function after low-dose captopril in heart failure. Am J Med 1984;77:880-6.
28. Cleland JG, Shah D, Krikler S, et al. Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J 1993;69:512-5.
29. Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-12.
30. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-9.
31. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin- converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
32. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.
33. Sakamoto T, Chen C, Lokhandwala MF. Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 1994;350:84-9.
34. Cleland JG, Poole Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994;72:S106-10.
35. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-49.
36. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996;94:690-7.
37. Swedberg K, Eneroth P, Kjekshus J, The CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with chronic congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
38. Komajda M, Wimart MC, Thibout E. L'tude ATLAS (assessment of treatment with lisinopril and survival); justification et objectifs. Arch Mal Coeur Vaiss 1994;87:45-50.
39. Magnani B, Magelli C. Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. Postgrad Med J 1986;62(Suppl 1):153-8.
40. Massie BM, Kramer BL, Topic N. Long-term captopril therapy for chronic congestive heart failure. Am J Cardiol 1984;53:1316-20.